Purpose Metaplastic breast carcinomas are an aggressive subtype of triple-negative breast cancer (TNBC) in which part or all of the adenocarcinoma transforms into a non-glandular component (e.g., spindled, squamous, or heterologous). We discovered that mammary-specific Ccn6/Wisp3 knockout mice develop mammary carcinomas with spindle and squamous differentiation that share upregulation of the oncofetal proteins IGF2BP2 (IMP2) and HMGA2 with human metaplastic carcinomas. Here, we investigated the functional relationship between CCN6, IGF2BP2, and HMGA2 proteins in vitro and in vivo, and their expression in human tissue samples. Methods MMTV-cre;Ccn6 fl/fl tumors and spindle TNBC cell lines were treated with recombinant CCN6 protein or vehicle. IGF2BP2 was downregulated using shRNAs in HME cells with stable CCN6 shRNA knockdown, and subjected to invasion and adhesion assays. Thirty-one human metaplastic carcinomas were arrayed in a tissue microarray (TMA) and immunostained for CCN6, IGF2BP2, and HMGA2. Results CCN6 regulates IGF2BP2 and HMGA2 protein expression in MMTV-cre;Ccn6 fl/fl tumors, in MDA-MB-231 and − 468, and in HME cells. CCN6 recombinant protein reduced IGF2BP2 and HMGA2 protein expression, and decreased growth of MMTV-cre;Ccn6 fl/fl tumors in vivo. IGF2BP2 shRNA knockdown was sufficient to reverse the invasive abilities conferred by CCN6 knockdown in HME cells. Analyses of the TCGA Breast Cancer Cohort (n = 1238) showed that IGF2BP2 and HMGA2 are significantly upregulated in metaplastic carcinoma compared to other breast cancer subtypes. In clinical samples, low CCN6 is frequent in tumors with high IGF2BP2/HMGA2 with spindle and squamous differentiation. Conclusions These data shed light into the pathogenesis of metaplastic carcinoma and demonstrate a novel CCN6/IGF2BP2/ HMGA2 oncogenic pathway with biomarker and therapeutic implications.
Introduction
Metaplastic breast carcinoma is a rare form of breast cancer that exhibits transformation of part or all of its glandular carcinomatous component into a non-glandular, or metaplastic, component [1, 2] . The metaplastic component(s) is most commonly spindle and/or squamous, or heterologous, which include chondroid and osseous elements. These
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carcinomas account for approximately 1% of breast carcinomas, but up to 14% of breast carcinomas in African and African American women, they are almost invariably triplenegative (TNBC) for estrogen and progesterone receptors (ER and PR), and negative for HER2/neu overexpression [3, 4] . Compared to other subtypes of TNBC, metaplastic breast carcinomas are the most aggressive and most chemoresistant, with high propensity for metastasis [2, 5] .
Located on chromosome 6p21-23, Ccn6/Wisp3 encodes a matricellular protein that is secreted by mammary epithelial cells and mediates epithelial-stromal cross-talk by binding to growth factors (e.g., bone morphogenetic protein 4) and/or cell surface receptors including integrins [6] [7] [8] [9] . CCN6 plays important roles in development, maintenance of an epithelial phenotype, and cell attachment to the matrix. We have shown that normal breast epithelium secretes CCN6 to the extracellular medium, and that low levels of CCN6 characterize biologically aggressive breast cancers, including inflammatory breast carcinomas and metaplastic carcinomas [7, 10, 11] . Our lab has generated a novel MMTV-cre;Ccn6 fl/fl knockout mouse using the Cre-lox system to specifically study the effect of Ccn6 deletion in the mammary epithelium [12] . Using this model, we discovered that Ccn6 is important for normal mammary gland development and tumorigenesis. MMTV-cre;Ccn6 fl/fl mice mammary glands had fewer terminal buds, decreased breast complexity, and displayed ductal hypoplasia when compared to wild-type mice. Significantly, MMTV-cre;Ccn6 fl/fl mice developed mammary tumors morphologically and transcriptionally similar to high-grade spindle and squamous human metaplastic carcinomas [12] . Transcriptomic analyses of MMTV-cre;Ccn6 fl/fl tumors and comparison with transcriptional profiles of human metaplastic carcinomas revealed 87 concordantly deregulated genes. Of these, IGF2BP2 and HMGA2 are the top upregulated genes in human and mouse metaplastic carcinomas [12] .
IGF2BP2 (insulin-like growth factor 2 mRNA binding protein 2/IMP2) is an oncofetal protein important for embryonic development and downregulated in normal adult tissues, which functions by binding and stabilizing mRNAs to extend their half-life [13, 14] . Previous studies have shown that IGF2BP2 is elevated in multiple types of carcinomas and that it is associated with cancer growth, migration, adhesion, and energy metabolism [14] . In breast cancer, IGF2BP2 overexpression is associated with decreased cell adhesion and migration [14] . HMGA2 (high mobility group AT-Hook 2), another oncofetal protein, functions as an architectural transcription factor [15] . Similar to IGF2BP2, HMGA2 contributes to embryonic development and tumorigenesis [15] . HMGA2 levels are associated with migration, EMT, and worse outcome in breast cancer [15] .
IGF2BP2 and HMGA2 have a reciprocal relationship, as IGF2BP2 prevents Let7-mediated HMGA2 inhibition [16] , and IGF2BP2 gene transcription and protein expression are highly dependent on HMGA2 [17] . IGF2BP2 possesses an AT-rich region in the first intron of its DNA sequence, which allows for HMGA2-mediated regulation. Binding of HMGA2 to this site uncovers a consensus-binding site for NF-kB, inducing expression of IGF2BP2 [17] . However, whether CCN6 regulates IGF2BP2/HMGA2 signaling, and their possible role in metaplastic carcinomas has not been considered previously. Here, we tested the hypothesis that low CCN6 expression alone or coupled with high IGF2BP2/ HMGA2 may identify a subset of metaplastic carcinomas with spindle/squamous features, and that activation of IGF2BP2/HMGA2 signaling may mediate the invasive abilities of this aggressive form of breast cancer.
Materials and methods

Cell culture, generation of stable transfectants, and immunoblots
MDA-MB-231, MDA-MB-468, and HME cells were purchased from the American Type Culture Collection and grown under recommended conditions. Cell lines were authenticated using STR profiling, and were tested for mycoplasma infection using Sigma LookOut Mycoplasma PCR Detection Kit (Cat MP0035). CCN6 shRNA and scrambled controls were reported previously [18] . The scrambled control vector shRNA-SC and IGF2BP2 knockdown shRNA plasmid pLKO.1-puro was purchased from Sigma (St. Louis, MO) and packaged at the University of Michigan Vector Core. For stable transductions, the virus-containing supernatant was diluted 1:1 with fresh media and supplemented with 8 µg/mL polybrene to infect HME cells. Selection was initiated in 10 µg/mL puromycin (Sigma-Aldrich Co., St. Louis, MD) 48 h after infection. Recombinant CCN6 protein (rCCN6) (200 ng/mL) was purchased from PeproTech, and used as in our previous studies [18] .
For MDA-MB-231 and − 468 breast cancer cells and for HME non-tumorigenic breast cells, Western blot analyses were carried out with 100 µg of whole cell extract derived as previously reported [19] . Primary antibodies used include CCN6, IGF2BP2, HMGA2 (Abcam, #ab187666, #ab129071, #ab97276, respectively), E-cadherin, ZEB1, SNAI2/Slug (Cell Signaling, #3195, #3396, #9585 respectively), and β-Actin (Santa Cruz Biotechnology, #SC-47778).
Invasion and adhesion assays
In vitro invasion was measured using 24-well matrigelcoated invasion chambers (BD Biosciences, Bedford, MA) according to the manufacturer's instructions, in triplicate.
Invasive cells on lower sides of chambers were stained with 0.05% crystal violet, air-dried, photographed, and then counted under a microscope. Cell attachment assays were performed by trypsinizing 70% confluent cell dishes and seeding 1 × 10 5 cells in a 12-well plate. After 30 min, nonadherent cells were removed by washing wells with PBS three times. Adherent cells were imaged and entire wells were quantified using ImageJ.
In vivo transplantation and CCN6 treatment studies
MMTV-Cre;Ccn6
fl/fl mice tumors were collected and implanted into the mammary fat pads of 8-10 week old virgin female syngeneic MMTV-Cre;Ccn6 fl/fl mice (n = 18). Two weeks after implantation, mice were treated with rhCCN6 (1 ng/g, i.v., twice a week) or BSA (1 ng/g) in the same regimen, and followed by palpation and caliper measurements for 3 weeks. Organoids derived from MMTV-Cre;Ccn6 fl/fl mice tumors were generated following previous reports [20] .
Study population and immunohistochemistry
Metaplastic breast carcinoma tissues from the Surgical Pathology files at the University of Michigan were retrieved. We identified 31 cases from 1988 to 2015 with available blocks. All tumor slides were reviewed and classified according to the predominant metaplastic component into spindle, squamous, or chondroid [1, 21] . Representative areas were selected to construct a high density tissue microarray (TMA) with duplicate samples. A total of 31 cases (n = 77 tissue microarray elements) comprised our patient cohort. Clinical and outcome information on the patients was obtained with institutional review board approval. Patient characteristics including age, race, treatment, and clinical follow-up (i.e., recurrence, death) as well as tumor characteristics including, size, nodal involvement, hormone receptor status, and HER-2/neu expression were recorded.
Human tumors arranged in the TMA as well as MMTVCre;Ccn6 fl/fl tumors were subjected to immunohistochemistry to detect CCN6, IGF2BP2, and HMGA2. Five micron-thick paraffin-embedded sections were de-paraffinized in xylene and rehydrated through graded alcohols to water. Heat-induced epitope retrieval (HIER) was performed in the Decloaking Chamber (Biocare Medical) with FLEX FTRS Low pH Retrieval buffer, pH6.1 (Dako, North America). Slides were incubated in 3% hydrogen peroxide for 5 min to quench endogenous peroxidases. Anti-CCN6 (Abcam # ab224720, dilution 1:400), anti-IGF2BP2 (Abcam # ab129071, dilution 1:100), and anti-HMGA2 (Abcam # ab97276, dilution 1:500) were incubated with the TMAs for 1 h at room temperature. Antibodies were detected with Envision + HRP Labeled Polymer (DakoCytomation) for 30 min at room temperature. HRP staining was visualized with the DAB + Kit (DakoCytomation).
Negative control slides were run. Slides were counterstained in hematoxylin, blued in running tap water, dehydrated through graded alcohols, cleared in xylene and then mounted with Permount. CCN6, IGF2BP2, and HMGA2 staining were evaluated at least two times for every tissue microarray element and at least four times for each tumor by 2 pathologists (EM and CGK), blinded to tumor stage and clinical information. CCN6 and IGF2BP2 displayed cytoplasmic staining, while HMGA2 was nuclear. For all proteins, expression was scored from 0 to 3 as follows: score 0 no staining, score 1 weak staining, score 2 moderate staining, and score 3 strong staining. Any staining (score ≥ 1) observed for IGF2BP2 and HMGA2 was considered positive. Expression for CCN6 was evaluated as either low or high. Scores 2 and 3 were considered high and scores 0 and 1 were considered low, respectively. Statistical analyses were carried out using Fisher's exact test and McNemar's test.
Results
MMTV-cre;Ccn6 fl/fl metaplastic carcinomas express high levels of IGF2BP2 and HMGA2
MMTV-cre;Ccn6 fl/fl mice tumors recapitulate human highgrade triple-negative spindle/squamous metaplastic carcinomas [12] . However, whether they express IGF2BP2 and HMGA2 proteins is unknown. Here, we found that all MMTV-cre;Ccn6 fl/fl tumors showed increased expression of IGF2BP2 and HMGA2 by immunohistochemistry. IGF2BP2 protein was expressed in the cytoplasm of cancer cells, while HMGA2 was exclusively nuclear (Fig. 1a) . IGF2BP2 and HMGA2 expression were low in adjacent normal mammary epithelium of MMTV-cre;Ccn6 fl/fl metaplastic carcinomas (Fig. 1a) .
Our laboratory has previously reported that CCN6 knockdown in non-tumorigenic breast cells induces a spindle and invasive phenotype with up-regulation of the EMT transcription factors SNAI1 and ZEB1 [10, 22] . Consistent with their spindle morphology, MMTV-cre;Ccn6 fl/fl tumors also had upregulated expression ZEB1 and SNAI2 (Fig. 1a) . Immunostaining of organoids derived from MMTV-cre;Ccn6 fl/fl tumors demonstrated high expression of IGF2BP2 and HMGA2 proteins in the spindle cancer cells, similar to the observed expression in whole tumor sections (Fig. 1b) .
Recombinant human CCN6 protein regulates IGF2BP2 and HMGA2 expression, and is sufficient to reduce growth of MMTV-cre;Ccn6 fl/fl metaplastic carcinomas in vivo As CCN6 is a secreted protein, we used recombinant human CCN6 (rhCCN6) to elucidate its role on IGF2BP2 and HMGA2 regulation. We employed MDA-MB-231 and − 468 cells, which are TNBC cells with a spindle morphology and gene expression profiles of mesenchymal-like and basal type-A breast carcinomas, respectively [23] . Addition of rhCCN6 was sufficient to reduce IGF2BP2 and HMGA2 protein levels in both breast cancer cell lines (Fig. 2a) . Furthermore, ectopic overexpression of CCN6 in MDA-MB-231 cells reduced ZEB1 and SNAI2 protein levels compared to controls (Supplementary Fig. 1) .
To investigate the effect of rhCCN6 in vivo, we established an orthotopic syngeneic model by transplanting MMTVcre;Ccn6 fl/fl tumors into the mammary fat pads of mice with the same genetic background (FVB). Mice were treated with rhCCN6 (1 ng/g, i.v., twice a week, initiated 2 weeks after transplantation) or BSA in the same regimen. rhCCN6 significantly reduced tumor growth, induced a morphological change from spindled towards epithelial, and reduced the expression of IGF2BP2 and HMGA2, compared to BSA treatment (Fig. 2b) . Together, these data demonstrate that CCN6 regulates IGF2BP2 and HMGA2 signaling in spindle carcinoma cells and that rhCCN6 is sufficient to reduce tumor growth in vivo.
The effect of CCN6 knockdown on invasion and adhesion requires IGF2BP2 cell adhesions and reduced E-cadherin expression [12] . We have previously reported that CCN6 shRNA knockdown (KD) promotes invasion in HME cells [8] . However, the effect of CCN6 KD on cell adhesion and the mechanistic link with IGF2BP2/HMGA2 signaling is unknown. CCN6 KD in HME cells resulted in significant upregulation of IGF2BP2, HMGA2, the EMT transcription factors SNAI2 and ZEB1, and induced downregulation of E-cadherin compared to scrambled controls (Fig. 3a) . To elucidate whether the effects of CCN6 KD on cell adhesion, invasion, and E-cadherin expression require IGF2BP2, we downregulated IGF2BP2 in HME cells with CCN6 KD and controls using two independent shRNAs. IGF2BP2 shRNA rescued the effect of CCN6 KD on HMGA2, ZEB1, SNAI2, and partially rescued E-cadherin expression (Fig. 3a) .
To ascertain the function of the IGF2BP2 axis on the increased invasion and on the reduced cell adhesion due to CCN6 KD, we subjected these cells to Matrigel invasion and adhesion assays. IGF2BP2 KD reversed the reduced cell adhesion and the increased invasion of CCN6 KD HME cells compared to controls (Fig. 3b, c) . Fig. 3 The induction of EMT, increased invasion, and reduced adhesion due to CCN6 knockdown require IGF2BP2. a HME cells were transduced with lentivirus containing shRNA CCN6 or scrambled shRNA controls (Scr). shRNA CCN6 HME cells were then transduced with two independent IGF2BP2 shRNAs (#1 and #2) or shRNA controls. Immunoblots were performed using the indicated antibodies. b, c Cells in A were subjected to cell attachment assays and to Matrigel invasion assays. 
A CCN6 low/IGF2BP2 high/HMGA2 high phenotype is frequent in metaplastic carcinomas in clinical samples
Our lab has reported that CCN6 protein is expressed in normal breast lobules and in 67% of invasive carcinomas, while it is low in the majority of metaplastic carcinomas [12] . However, whether CCN6 expression is associated with tumor differentiation is unknown. Using an independent cohort of 31 metaplastic carcinomas arranged in TMAs, we show that low CCN6 is significantly associated with the histologic type of metaplastic carcinomas. Table 2) . We found that normal breast epithelium adjacent or away from cancer expressed CCN6 and was negative for IGF2BP2 and HMGA2 proteins (Fig. 4a) . In contrast, 22 of the 27 (81.5%) tumors with low CCN6 and spindle and/or squamous differentiation showed high expression of IGF2BP2 and/or HMGA2 ( Fig. 4a; Table 3 ). Supporting the data in human tissues, in silico analyses of the TCGA Breast Cancer cohort (n = 1238) using UCSC Xena browser, showed that high mRNA expression of IGF2BP2 and HMGA2 is significantly associated with metaplastic carcinomas compared to other histological subtypes of breast cancer (Fig. 4b) . Consistent with the histological EMT observed in metaplastic carcinomas, they exhibit significantly higher SNAI2 and lower CDH1 expression than other breast cancer subtypes (Fig. 4b) .
Discussion
Metaplastic carcinomas are the most aggressive subtype of TNBC with a reported 5-year overall survival of 54% compared to 73.3% for TNBC [5] , but their pathobiology is still ill defined. This is due in part to the uncommon nature of these tumors, and the limited availability of mouse models that faithfully recapitulate human metaplastic carcinomas with spindle, squamous, or heterologous elements. Our lab has shown that metaplastic carcinomas exhibit mutations in Wnt pathway genes, including point mutations of Ccn6/Wisp3 [24] , and that conditional, mammary-epithelial cell specific Ccn6/Wisp3 knockout induced development of metaplastic spindle and squamous carcinomas, similar to human disease [12] . In the present study, we utilized this model to discover specific deregulated pathways and tested their significance to human metaplastic carcinomas.
The origin of metaplastic breast carcinomas is currently unknown. There are no pathognomonic precursors, gene mutations, or recurrent gene fusions that have been described for metaplastic breast carcinomas, and it is unclear if different mutations contribute to the distinct histological subtypes of these tumors [25] . Genomic analyses of human tumors showed that metaplastic carcinomas and non-metaplastic TNBCs share TP53 mutations [26] [27] [28] [29] [30] .
In addition, metaplastic carcinomas harbor more frequent PI3K and Wnt pathway gene mutations than non-metaplastic TNBC [24, 27] . However, specific pathways operative in spindle and squamous metaplastic carcinomas have not been reported to date. Transcriptional profiling of MMTVcre;Ccn6 fl/fl tumors [12] and comparison to a previously reported gene expression profile of human metaplastic carcinomas [26] led to the identification of IGF2BP2 and HMGA2 as the two top upregulated genes common to mouse and human tumors. Using cell lines and human tissue samples, we demonstrate that CCN6 downregulation leads to upregulation of IGF2BP2 and HMGA2 proteins. We validated the expression of these proteins in MMTVcre;Ccn6 fl/fl tumors and in a cohort of 31 human metaplastic carcinomas. Our analyses demonstrate that low CCN6 protein is frequent in tumors with a spindle and squamous phenotype with high IGF2BP2 and/or HMGA2 proteins. The limited number of tumors with chondroid differentiation do not allow us to conclude whether this pathway is operative in these cases as well.
A salient feature of metaplastic carcinomas is the enrichment for markers of stemness and EMT. Using clinical samples, our lab has reported the presence of ALDH1 positive and CD44 + /CD24 −/low expressing cells in the metaplastic component compared to the glandular component, strongly suggesting that the metaplastic cells are less differentiated than the cells forming glands [21] . We also found that in contrast with the E-cadherin positive/ZEB1 negative glandular component, the spindle cells in metaplastic carcinomas showed loss of E-cadherin and upregulation of ZEB1 [21] . Studies by other investigators validated these initial results using gene expression analyses of human tumors showing that metaplastic carcinomas exhibit a mesenchymal stem cell-like gene expression profile with upregulation of stem cell and EMT genes [23] . In the present study, we further demonstrate that MMTVcre;Ccn6 fl/fl tumors have overexpression of ZEB1 and SNAI2/Slug, and that the effect of CCN6 knockdown on the expression of these proteins and on breast cancer cell invasion requires IGF2BP2. The mechanistic link between CCN6, IGF2BP2, and HMGA2 is intriguing in light of their regulation and functions. IGF2BP2 and HMGA2 are oncofetal proteins with central roles during embryonic development, which are reduced in normal adult tissues and are re-expressed in cancer [13] [14] [15] . IGF2BP2 and HMGA2 exhibit reciprocal regulation, and their expression is controlled by activation of bone morphogenetic protein (BMP), insulin-like growth factor (IGF), insulin, and Wnt/β-catenin signaling pathways [13, 16] . CCN6 was detected during zebrafish development, where it was shown to play a role in pharyngeal cartilage development [31] . We have detected CCN6 expression in the developing murine mammary gland, and mammary epithelial cell-specific CCN6 knockout resulted in developmental defects, demonstrating a role for CCN6 during normal mammary gland development in mice [12] . Adult human breast cells express CCN6 and are able to secrete the protein into the extracellular matrix to regulate the effect of growth factor signaling pathways on the breast epithelia. Our lab and other investigators have demonstrated that conditioned medium containing CCN6 or human recombinant CCN6 protein is sufficient to inhibit BMP by binding to BMP ligand, and to reduce IGF1R activation [7, 8] . Although it remains to be shown in the human breast, CCN6 protein derived from zebrafish and human recombinant CCN6 protein antagonized Wnt/ β-catenin signaling by interacting with low density lipoprotein receptor 6 (LRP6) and Frizzled 8 in HEK293T human embryonic kidney cells [31] . This warrants further investigation in light of the possible role of Wnt signaling in metaplastic carcinomas.
Available data in human tissues support that upregulation of IGF2BP2 and HMGA2 may lead to enhanced tumor progression and may serve as a prognostic biomarker. Analysis of publicly available breast cancer expression datasets showed that IGF2BP2 is elevated in TNBC where it is associated with worse survival [32, 33] and that HMGA2 predicts relapse-free survival and metastasis in patients with TNBC [34] . HMGA2 expression was found significantly associated with the gene expression signature of metaplastic carcinomas [35] . We demonstrate that elevated mRNA expression of IGF2BP2 and HMGA2 is significantly associated with metaplastic carcinoma compared to other breast cancer subtypes, and that low CCN6 protein coupled with high IGF2BP2 and/or HMGA2 proteins marks human metaplastic carcinomas. Taken together, our study delineates a previously unconsidered pathway involved in the development of metaplastic carcinomas with diagnostic and therapeutic implications. 
